« Return to News | Drug Sponsors

Shire to buy Advanced BioHealing

Wednesday, May 18, 2011 12:10 PM

Ireland-based Shire will acquire the U.S.-based Advanced BioHealing for $750 million in cash, according to Pharma Times.

Shire’s interest is in Advanced BioHealing’s Dermograft, a regenerative bio-engineered skin substitute used for the treatment of diabetic foot ulcers. Shire says Dermagraft has a "favorable reimbursement profile," notably with Medicare (100% coverage), and that generic products "would have to overcome high regulatory, development and manufacturing hurdles" to enter the DFU market.

Advanced BioHealing also has fully enrolled multinational trials to investigate Dermagraft to treat venous leg ulcers.

Mike Cola, president of Shire's specialty pharmaceuticals business, said the acquisition is "a strong and complementary strategic fit." He claimed that "the potential to build on the success of Dermagraft is attractive" as it provides a solution for a common complication suffered by diabetics that, "if not treated effectively, can lead to lower limb amputation and high cost to patients and society."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.